On Monday, Autolus Therapeutics plc ADR (NASDAQ: AUTL) was 2.48% up from the session before settling in for the closing price of $4.44. A 52-week range for AUTL has been $2.56 – $7.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 190.29%. When this article was written, the company’s average yearly earnings per share was at 31.59%. With a float of $236.60 million, this company’s outstanding shares have now reached $266.05 million.
The extent of productivity of a business whose workforce counts for 463 workers is very important to gauge. In terms of profitability, gross margin is 52.27%, operating margin of -1518.81%, and the pretax margin is -1845.81%.
Autolus Therapeutics plc ADR (AUTL) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Autolus Therapeutics plc ADR stocks. The insider ownership of Autolus Therapeutics plc ADR is 11.07%, while institutional ownership is 55.67%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.26 earnings per share (EPS) during the time that was less than consensus figure (set at -0.25) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 31.59% per share during the next fiscal year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
You can see what Autolus Therapeutics plc ADR (AUTL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 18.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 115.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
The latest stats from [Autolus Therapeutics plc ADR, AUTL] show that its last 5-days average volume of 0.98 million was inferior to 1.35 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 39.28%. Additionally, its Average True Range was 0.24.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 76.00%, which indicates a significant increase from 58.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.25% in the past 14 days, which was lower than the 60.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.03, while its 200-day Moving Average is $4.69. Now, the first resistance to watch is $4.69. This is followed by the second major resistance level at $4.84. The third major resistance level sits at $4.98. If the price goes on to break the first support level at $4.40, it is likely to go to the next support level at $4.26. The third support level lies at $4.11 if the price breaches the second support level.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
There are 266,036K outstanding shares of the company, which has a market capitalization of 1.21 billion. As of now, sales total 1,700 K while income totals -208,380 K. Its latest quarter income was 10,090 K while its last quarter net income were -52,690 K.
